Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs